Randomized Study Found Surgery-Sparing Active Monitoring Safe in Patients With Low-risk DCIS

SAN ANTONIO, USA—In patients with hormone receptor-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS) active monitoring, compared with surgery, resulted in no difference in terms of cancer outcomes in the multicenter, randomized COMET study that compared oncologic outcomes of patients randomized to guideline-concordant care (with surgery alone or with radiation therapy) or active monitoring. COMET investigated 995 patients with grade one or two DCIS with no evidence of invasive cancer. After reporting the findings at the 2024 San Antonio Breast Cancer Symposium, study author E. Shelley Hwang MD MPH, Breast Surgeon and Director of the Breast Oncology Program at Duke University gave more details to Audio Journal of Oncology Editor, Peter Goodwin: PODCAST EPISODE: Audio Journal of Oncology interview with E. Shelley Hwang MD MPH 2024 San Antonio Breast Cancer Symposium ABSTRACT： GS2-05: Early Oncologic Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS: the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25)